<DOC>
	<DOCNO>NCT02452476</DOCNO>
	<brief_summary>A multicenter , double blind , randomize , single dose , active-controlled study investigate efficacy safety synthetic surfactant ( CHF 5633 ) comparison porcine surfactant ( Poractant alfa , Curosurf ® ) treatment preterm neonates respiratory distress syndrome . Main objective study investigate short term efficacy profile CHF 5633 vs. porcine surfactant ( Poractant Alfa , Curosurf® ) term reduce oxygen requirement ventilatory support evaluate mid-term efficacy profile term reduce incidence bronchopulmonary dysplasia ( BPD ) mortality/BPD rate 36 week post menstrual age ( PMA ) , mortality rate 28 day 36 week PMA , RDS-associated mortality 14 day age major co-morbidities prematurity . Inclusion criterion : Written parental inform consent , inborn preterm neonates either sex gestational age 24+0 week 29+6 week , clinical course consistent RDS , requirement endotracheal surfactant administration within 24 hour birth , fraction inspire oxygen ( FiO2 ) ≥0.30 baby 24+0 26+6 week FiO2 ≥0.35 baby 27+0 29+6 week maintain SpO2 88-95 % .</brief_summary>
	<brief_title>A Double Blind , Randomized , Controlled Study Compare CHF 5633 ( Synthetic Surfactant ) Poractant Alfa RDS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Poractant alfa</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<criteria>1 . Written inform consent obtain parents/legal representative ( accord local regulation ) prior studyrelated procedure 2 . Inborn preterm neonates either sex gestational age 24+0 week 29+6 week 3 . Clinical course consistent RDS 4 . Requirement endotracheal surfactant administration within 24 hour birth 5 . Fraction inspire oxygen ( FiO2 ) ≥0.30 baby 24+0 26+6 week FiO2 ≥0.35 baby 27+0 29+6 week maintain SpO2 8895 % 1 . Use surfactant prior study entry need intratracheal administration treatment ( e.g . nitric oxide ) 2 . Known genetic chromosomal disorder , major congenital anomaly ( cardiac malformation , myelomeningocele etc ) 3 . Maternal drug abuse ( heroin , methadone , methamphetamine , cocaine ) significant alcohol consumption pregnancy 4 . Mothers prolong rupture membrane ( &gt; 21 day duration ) 5 . Strong suspicion congenital pneumonia/infection , sepsis 6 . Presence air leak prior study entry 7 . Evidence severe birth asphyxia 8 . Neonatal seizure prior study entry 9 . Any condition , opinion Investigator , would place neonate undue risk 10 . Participation another clinical trial placebo , drug biological substance conduct provision protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>